The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2019. Visit CONQUER.ORG/CCA for more details.
Immunotherapy for Head and Neck Cancer
Dr. Cohen speaks at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. He received a Conquer Cancer Young Investigator Award in 2003 supported by MGI Pharma, Inc, and a 2005 Career Development Award supported by Sanofi-Aventis.
At the Moores Cancer Center at UC (University of California) San Diego Health, Ezra E. Cohen, MD, led a large clinical trial of patients with relapsed or metastatic head and neck cancer.
The research team compared the efficacy and safety of the programmed cell death protein 1 inhibitor pembrolizumab vs standard-of-care therapy for the treatment of head and neck squamous cell carcinoma.
Study results demonstrated clinically meaningful prolongation of overall survival and a favorable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
© 2019. American Society of Clinical Oncology. All rights reserved.